Key Takeaways
- Sermorelin is GRF (1-29) amide: the first 29 residues of human growth hormone-releasing hormone with a C-terminal amide (CAS 86168-78-7, C149H246N44O42S, 3357.9 Da). It is the shortest fragment of GHRH that retains the full intrinsic activity of the 44-residue hormone, which is what made it the reference GHRH analog rather than a curiosity..
- Sourcing specification: ≥99% purity by HPLC. Measured purity is reported on the lot's Certificate of Analysis where one is on file.
- Third-party Certificates of Analysis are published where on file. Same-day US shipping.
Sermorelin Specifications
Sermorelin (CAS 86168-78-7) is studied in in-vitro and animal models via GHRH (1-29) analog. This section covers molecular identity and specification data. Analytical standard: ≥99% HPLC specification; CoA where on file. Stocked material is for laboratory research use only. Identity, structure, and handling values come from the existing profile.
- Compound
- Sermorelin
- CAS Number
- 86168-78-7
- Molecular Formula
- C149H246N44O42S
- Molecular Weight
- 3357.9 Da
- Sequence / Structure
- GRF (1-29) NH2 — 29-amino-acid GHRH analog
- Mechanism Class
- GHRH (1-29) analog
- Purity
- ≥99% HPLC specification; CoA where on file
Sermorelin molecular identity and purity specifications
Registry records for Sermorelin: PubChem
Sermorelin Mechanism of Action
Sermorelin (CAS 86168-78-7) is studied in in-vitro and animal models via GHRH (1-29) analog. This section covers the reported mechanism and its evidence limits. Analytical standard: ≥99% HPLC specification; CoA where on file. Stocked material is for laboratory research use only. Identity, structure, and handling values come from the existing profile.
Sermorelin is native sequence rather than engineered sequence, and that fact is both its pharmacology and its limitation. It binds the GHRH receptor on pituitary somatotrophs, couples through Gs to adenylate cyclase, raises cAMP and triggers a growth hormone pulse that follows the hypothalamic pattern.
Because position 2 carries the unmodified alanine of the native hormone, dipeptidyl peptidase-4 cleaves it quickly and its circulating half-life is measured in minutes. Every other GHRH analog stocked here is an answer to that single problem: CJC-1295 (No DAC) substitutes D-Ala2 along with three other residues, and tesamorelin blocks the same cleavage with an N-terminal acyl group instead.
Sermorelin Research Applications
Sermorelin (CAS 86168-78-7) is studied in in-vitro and animal models via GHRH (1-29) analog. This section covers the model systems and analytical readouts. Analytical standard: ≥99% HPLC specification; CoA where on file. Stocked material is for laboratory research use only. Identity, structure, and handling values come from the existing profile.
GHRH receptor signaling, where sermorelin is the unmodified native ligand and therefore the honest control for every stabilized analog.
Somatotropic axis models asking whether release remains pulsatile, a question a short-lived agonist can address and a long-acting one cannot.
Protease-stability studies using DPP-4 cleavage at the position-2 alanine as the model reaction.
Pituitary reserve assays, the application sermorelin was originally developed to serve as a diagnostic agent.
Sermorelin Storage Requirements
Sermorelin (CAS 86168-78-7) is studied in in-vitro and animal models via GHRH (1-29) analog. This section covers the material's structure-specific handling requirements. Analytical standard: ≥99% HPLC specification; CoA where on file. Stocked material is for laboratory research use only. Identity, structure, and handling values come from the existing profile.
Store lyophilized sermorelin at -20°C (-4°F). Reconstituted, hold at 2-8°C (36-46°F) and use within 30 days. Sermorelin keeps the native methionine at position 27 that CJC-1295 (No DAC) replaces with leucine, so methionine sulfoxide is the impurity to expect in an aged solution; keep vials sealed and avoid diluents carrying trace copper or iron.
Sermorelin at Peptide.Express
Sermorelin is sourced against a ≥99% HPLC purity specification. Third-party Certificates of Analysis are listed by batch where on file. Same-day US shipping on orders before 2 PM EST. For laboratory research use only. Not for human or veterinary use.
Sermorelin Frequently Asked Questions
What is Sermorelin?
Sermorelin is GRF (1-29) amide, the first 29 residues of human growth hormone-releasing hormone with a C-terminal amide. Its CAS number is 86168-78-7, its molecular formula is C149H246N44O42S and its average molecular weight is 3357.9 Da. It is the shortest GHRH fragment that retains the full activity of the 44-residue hormone.
What is the sequence of Sermorelin?
Sermorelin is YADAIFTNSYRKVLGQLSARKLLQDIMSR-NH2, the first 29 amino acids of human GHRH (1-44) with the C-terminus amidated. Truncating the hormone at residue 29 does not reduce intrinsic activity, which is why the fragment rather than the full hormone became the standard analog.
Is Sermorelin FDA approved?
Sermorelin acetate was previously approved in the United States as Geref and used in assessing pituitary growth hormone reserve; that product was subsequently discontinued and withdrawn from the market. No sermorelin drug product is currently approved by the FDA. Research-grade sermorelin is not a medicine and is supplied for in-vitro laboratory research only.
What is the difference between Sermorelin and CJC-1295?
Sermorelin is the native GRF (1-29) sequence at 3357.9 Da. CJC-1295 (No DAC) is the same 29 positions with four substitutions — D-Ala2, Gln8, Ala15, Leu27 — that block DPP-4 cleavage, remove a deamidation site and remove the oxidation-prone methionine, giving 3367.9 Da. Full CJC-1295 with DAC adds an albumin-binding group and is a different molecule again at roughly 3647 Da.
References
- Mayo KE. "Molecular Cloning and Expression of a Pituitary-Specific Receptor for Growth Hormone-Releasing Hormone." Molecular Endocrinology, 1992. Read the GHRH receptor cloning and cAMP-signaling study on PubMed
- Wehrenberg WB, Ling N. "In Vivo Biological Potency of Rat and Human Growth Hormone-Releasing Factor and Fragments of Human Growth Hormone-Releasing Factor." Biochemical and Biophysical Research Communications, 1983. Read the GRF fragment structure-activity study on PubMed
Sermorelin Compared
Research Areas Using Sermorelin
Related Research Guides
How This Page Is Sourced
Molecular identity on this page (name, CAS number, molecular formula and molecular weight) is resolved from a single internal entity record and checked against primary registries (PubChem, CAS Common Chemistry) rather than retyped per page. A field with no verified value is left out instead of estimated. Literature is cited to a DOI, PMID or PMCID permalink so every reference resolves to the specific record it names.
